T-group (topology)
9.13.1 AOC barrel-like
Ligands and drugs
416
Member domains
126
with ligand contacts (≤ 4 Å)
30.3% of members
110
with DrugDomain annotations
26.4% of members
88
with a DrugBank compound
21.2% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 9.13.1 belongs to X-group 9 Lipocalins/Streptavidin, which binds 9.3 ligand superclasses per 20 proteins, broader than 86% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB02210 | HEZ | Hexane-1,6-Diol | 15 |
| DB00145 | GLY | Glycine | 2 |
| DB01692 | DTU | Dithioerythritol | 2 |
| DB04473 | FUC | alpha-L-fucose | 2 |
| DB03789 | DMI | 2,3-Dimethylimidazolium Ion | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| HEZ | HEXANE-1,6-DIOL | 15 |
| 10Y | (9Z)-11-{(2R,3S)-3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}undec-9-enoic acid | 7 |
| CAmetal | CALCIUM ION | 6 |
| CL | CHLORIDE ION | 5 |
| 4W9 | (4S,4aS,6aS,8R,9R,10aR,13R,14aS,18aR,18bR)-9-ethyl-4,8,19-trihydroxy-10a,12,13,18a-tetramethyl-2,3,4,4a,5,6,6a,7,8,9,10,10a,13,14,18a,18b-hexadecahydro-1H-14a,17-(metheno)benzo[b]naphtho[2,1-h]azacyclododecine-16,18(15H,17H)-dione | 4 |
| A3I | (4S,4aS,6aR,8R,9R,10aS,13S,14aS,18aR,18bR,E)-9-ethyl-4,8,19-trihydroxy-10a,12,13,18a-tetramethyl-2,3,4,4a,6a,7,8,9,10,10a,13,14,18a,18b-tetradecahydro-14a,17-(metheno)benzo[b]naphtho[2,1-h][1]azacyclododecine-16,18(1H,15H)-dione | 4 |
| BR | BROMIDE ION | 4 |
| GLY | GLYCINE | 4 |
| HOF | methyl 4-[[(1S,6S)-6-(dimethylcarbamoyl)cyclohex-2-en-1-yl]carbamoyloxymethyl]benzoate | 4 |
| 10X | (9Z)-11-{(2S,3S)-3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}undec-9-enoic acid | 3 |
| 6QF | phenazin-1-ol | 3 |
| 8IF | (Z,2R,4S)-1-(4-methoxy-5-methylidene-2-oxidanylidene-furan-3-yl)-2,4-dimethyl-dodec-6-ene-1,5-dione | 3 |
| MRD | (4R)-2-METHYLPENTANE-2,4-DIOL | 3 |
| 9LC | (4S,4aS,6aR,8R,9R,11E,12aR,14aS,17E,18aR,18bR)-9-ethyl-4,8,19-trihydroxy-11,12a,13,18a-tetramethyl-2,3,4,4a,6a,7,8,9,10,12a,13,14,18a,18b-tetradecahydro-14a,17-(metheno)cyclobuta[b]naphtho[2,1-j][1]azacyclotetradecine-16,18(1H,15H)-dione | 2 |
| DTU | (2R,3S)-1,4-DIMERCAPTOBUTANE-2,3-DIOL | 2 |
| SER | SERINE | 2 |
| T25 | (9Z)-11-[(2R,3S)-3-pentyloxiran-2-yl]undec-9-enoic acid | 2 |
| WHW | 9S,13R-12-OXOPHYTODIENOIC ACID | 2 |
| A1EMO | 6-[(2E,4E,6E)-6-methylocta-2,4,6-trien-2-yl]-4-oxidanyl-pyran-2-one | 1 |
| DMI | 2,3-DIMETHYLIMIDAZOLIUM ION | 1 |